A phase 2 study of anti-siglec-15 antibody, nc318, in combination with pembrolizumab (nct04699123) demonstrates clinical activity in patients with advanced pd-1 axis inhibitor refractory nsclc

• data presented at the 2023 world conference on lung cancer hosted by the international association for the study of lung cancer in singapore
NXTC Ratings Summary
NXTC Quant Ranking